Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Prostatype Genomics AB's Enterprise Value is kr21.68 Mil.
Prostatype Genomics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-42.89 Mil. Therefore, Prostatype Genomics AB's EV-to-EBIT ratio for today is -0.51.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Prostatype Genomics AB's Enterprise Value is kr21.68 Mil.
Prostatype Genomics AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-40.70 Mil. Therefore, Prostatype Genomics AB's EV-to-EBITDA ratio for today is -0.53.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Prostatype Genomics AB (OSTO:PROGEN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Prostatype Genomics AB's current Enterprise Value is kr21.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-42.89 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Prostatype Genomics AB's EV-to-EBITDA for today is:
Prostatype Genomics AB's current Enterprise Value is kr21.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-40.70 Mil.
Prostatype Genomics AB's current Enterprise Value is kr21.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.59 Mil.
Prostatype Genomics AB's current Enterprise Value is kr21.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was kr-23.80 Mil.
Prostatype Genomics AB's current Enterprise Value is kr21.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-37.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB Enterprise Value Related Terms
Prostatype Genomics AB Enterprise Value Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Enterprise Value falls into.
Prostatype Genomics AB Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Prostatype Genomics AB's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a Enterprise Value of kr21.68 Mil as of Jul. 01, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Enterprise Value too high?
Prostatype Genomics AB's current Enterprise Value is kr21.68 Mil. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Enterprise Value compare to TMO and DHR?
Prostatype Genomics AB's Enterprise Value of kr21.68 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Enterprise Value is kr21.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current Enterprise Value is kr21.68 Mil. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Enterprise Value is kr21.68 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Enterprise Value: kr21.68 Mil
GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score
Get the complete analysis for OSTO:PROGEN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
